NCCN Pharmacy Updates: The Role of Tyrosine Kinase Inhibitors in Pediatric Acute Lymphoblastic Leukemia
Although therapy with tyrosine kinase inhibitors (TKIs) has been a common adoption in cancer treatment of Ph+ ALL, further research has helped expand the understanding of the role and limitations for these very agents, which now also play a major role in the treatment of the Ph-like ALL subtype. It is important for health care professionals caring for pediatric patients with ALL to recognize aspects of optimal dosing and frequency, appropriate use in particular genomic alterations, mechanisms of resistance, and patient-specific counseling points to ensure efficacy and compliance of TKIs.
This program is designed to meet the educational needs of pharmacists, physicians, nurses, nurse practitioners, physician assistants and other health care professionals who manage patients with cancer.
Following this activity, participants should be able to:
- Summarize the initial presentation, diagnostic criteria, and risk stratification of pediatric acute lymphoblastic leukemia (ALL).
- Describe the genomic alterations of pediatric Philadelphia chromosome-positive (Ph+) and Philadelphia chromosome-like (Ph-like) ALL.
- Distinguish the role, impact, and potential limitations of tyrosine kinase inhibitors in the treatment of pediatric Ph+ and Ph-like ALL.
Suzanne C. Gettys, PharmD, BCOP
The University of Texas MD Anderson Cancer Center
NCCN Medical Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.
In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing.
Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.
The faculty listed below have no relevant financial relationships with ineligible companies to disclose.
Suzanne C. Gettys, PharmD, BCOP
NCCN Staff Disclosures
None of the planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NCCN designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NCCN designates this educational activity for a maximum of 1.0 contact hour.
NCCN designates this application-based continuing education activity for 1.0 contact hour (0.10 CEUs) of continuing education credit. UAN: JA4008196-0000-22-079-L01-P
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim credit commensurate with the extent of their participation.
Available for an additional fee: (Save $10 per test by purchasing the 12-test bundle)
The Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Board of Pharmacy Specialties (BPS) as a provider of board certification oncology credit (BCOP). A BCOP statement of credit will be issued only upon completion of a post-activity evaluation form and post-test, with a passing grade of 75% achieved.
Disclosure of Conflicts of Interest: The Hematology/Oncology Pharmacy Association (HOPA) assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CE activities. All relevant conflicts of interest that are identified are thoroughly vetted by HOPA for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. HOPA is committed to providing its learners with high-quality CE activities and related materials that promote improvements of quality in healthcare and not a specific proprietary business interest of a commercial interest.
Reported Areas of Conflict: Hematology/Oncology Pharmacy Association does not view the existence of relationships as an implication of bias or that the value of the material is decreased. The content of the activity was planned to be balanced, objective, and scientifically rigorous. Occasionally, authors may express opinions that represent their own viewpoint. Conclusions drawn by participants should be derived from objective analysis of scientific data. Unlabeled/unapproved uses of drugs. All faculty have indicated that they have not referenced unlabeled/unapproved uses of drugs and devices.
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 Participation
This webinar was presented live one time only on Wednesday, August 24, 2022, from 1:30 – 2:30 PM EDT (UTC -4).
The recorded activity is available here.
NCCN Non-Discrimination/Harassment Policy – Affiliated Persons and Volunteers
NCCN is committed to providing workplaces and events that are free from discrimination or harassment of any kind for all participants, and has a zero-tolerance policy for any such conduct. NCCN requires individuals participating on NCCN Guidelines Panels, standing and ad hoc committees, meetings and seminars, or other NCCN-affiliated activities and events to adhere to this policy.
To access this policy including reporting procedures, please visit NCCN.org/non-discrimination.
To complete this activity, users will need:
- A device with an Internet connection and sound playback capability
- One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
- Internet Explorer is no longer supported
- Adobe Reader or other PDF reader software for certificate viewing/printing